HYDERABAD, India & BASEL, Switzerland & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited (ASX: MYX). Read more >
- The BUZZ / News
- Publications
- MarketplaceAutomationCompoundingContamination ControlDelivery & ShippingDistributionFacilitiesFinanceManufacturingMerchandisingPatient CareHighlighted Practice SettingsProfessional DevelopmentProfessional ServicesSoftware
- Business Management, Operations, ERP
- Clinical Monitoring, Surveillance, Insights
- Controlled Substance Reporting
- Clinical Decision Support, Point of Care Reference, Dosing, DUR
- Drug Diversion Monitoring, Diversion Prevention
- Error Prevention, Drug Validation
- eMAR, EMR, EHR, Bedside Verification
- Formulary Management
- IV Workflow Management
- Long-Term Care Operation Management
- Medication Inventory Management & Procurement
- Pharmacy Management Systems, Workflow
- Stewardship Resources (Antibiotic, Opioid, etc)
Unit DoseWorkflow - Multimedia Content
- Career Center
- Market Intelligence
- Company
